Home›Stock Screener›Valiant Laboratories

Valiant Laboratories Share Price Today | Stock Price & Valiant Laboratories Share Screener

VALIANTLAB Pharmaceuticals
Live Share Price NSE
₹107.87
▲ 2.39 (2.27%)
2026-08-26 00:00:00
Live Share Price BSE
₹125.50
▲ 3.40 (2.78%)
2026-10-05 00:00:00

As of August 26, 2026, the live Valiant Laboratories share price (NSE: VALIANTLAB) is ₹107.87 on NSE and ₹125.50 on BSE, up 2.27% from the previous close, with shares trading between ₹103.32 and ₹110.70 in today's trading session, and a 52-week range of ₹50.93–₹107.87. Check VALIANTLAB 52-week chart for the annual price range and momentum. Use the Valiant Laboratories stock screener below to analyse P/E ratio, market cap, quarterly results, and more. See at what price today Valiant Laboratories opened, then compare its market price and price volume with top gainers and top losers on the exchange. Record your trades in TickJournal's free trading journal and track your portfolio performance.

Key Statistics and Valuation Ratios

Over the trailing twelve months the company reported revenue of ₹116 and net income of ₹21, with EBITDA of ₹30, an operating margin of 25.0% and a profit margin of 18.1%.

Valiant Laboratories Market Cap ₹663.64 Cr.
VALIANTLAB P/E Ratio (TTM) 40.56
Valiant Laboratories P/B Ratio 2.09
EPS (TTM) ₹-0.51
Dividend Yield -
Debt to Equity 0.42
VALIANTLAB 52 Week High ₹107.87
Valiant Laboratories 52 Week Low ₹50.93
Operating Margin 25.00%
Profit Margin 18.10%
VALIANTLAB Revenue (TTM) ₹116.00
EBITDA ₹30.00
Net Income ₹21.00
Total Assets ₹464.00
Total Equity ₹311.00

Valiant Laboratories Share Price Chart

Track the current stock price of Valiant Laboratories with an interactive chart. Analyse VALIANTLAB share price trends, closing price, trading volume, historical performance, and volatility using live market data across different timeframes, from the last 30 days to the full record — the complete Valiant Laboratories stock quote in one place.

The quote of ₹107.87 sits between the 52-week low of ₹50.93 and the 52-week high of ₹107.87, and the latest session moved 2.27% from the previous close.

Valiant Laboratories Company Profile - Fundamental Screener

Screen Valiant Laboratories company fundamentals and business profile. Use our stock screener to analyze sector, industry, and key company metrics for VALIANTLAB shares across the equity market and its stock price history, plus the wider market trend.

The company is classified under the Healthcare sector and the Pharmaceuticals industry, and it trades under ISIN INE0JWS01017.

Company Details

Classification

Sector Healthcare
Industry Pharmaceuticals
Sub-Sector Pharmaceuticals
Segment E

Identifiers and Leadership

ISIN INE0JWS01017

Valiant Laboratories Balance Sheet Screener

Screen VALIANTLAB balance sheet fundamentals including assets, liabilities, and equity. Use our screener tool to analyze financial health and share price valuation metrics, then compare equity shares and the debt-to-equity rate against peers in the stock market.

For 2026, total assets were ₹464, up from ₹401 in 2025.

Latest statistics put total assets at ₹464 and shareholder funds at ₹311, with a leverage ratio of 0.42.

Item 2026 2025 2024 2023

Assets

Total Assets 464 401 343 213
Current Assets 228 193 226 151
Fixed Assets 233 48 50 48

Liabilities

Total Liabilities 0 0 0 0
Current Liabilities 34 107 77 62
Non-Current Liabilities 0 0 0 0

Shareholders' Equity

Total Equity 311 234 237 101
Share Capital 54 44 44 33
Reserves & Surplus 257 191 193 68

Valiant Laboratories Income Statement Screener - Profit & Revenue Analysis

Screen Valiant Laboratories income statement and profit fundamentals. Analyze VALIANTLAB quarterly results. Valiant Laboratories reports revenue growth, EBITDA, net profit margins, and EPS, and TickJournal's fundamental screener helps with stock evaluation and equity returns.

For 2026-Jun, revenue was ₹116 and net profit was ₹21, equal to earnings per unit of ₹3.89, at an operating margin of 25%.

In that period expenses were ₹86, interest cost ₹1 and tax ₹5. The next period listed, 2026-Mar, shows revenue of ₹92 and net profit of ₹2.

Item 2026-Jun 2026-Mar 2025-Dec 2025-Sept 2025-Jun 2025-Mar 2024-Dec 2024-Sept 2024-Jun 2024-Mar 2023-Dec 2023-Sept 2023-Jun 2023-Mar 2022-Dec

Revenue and Expenses

Revenue 116 92 53 47 48 56 37 25 22 33 42 63 54 92 72
Expenses 86 87 53 46 44 54 35 28 21 35 47 61 48 81 61

Operating Costs and Margins

EBITDA 30 5 0 1 3 2 2 -3 0 -2 -5 2 6 10 11
Operating Profit % 25.00% 5.00% -2.00% 0.00% 5.00% 7.00% 2.00% -31.00% -13.00% -15.00% -16.00% -2.00% 7.00% 10.00% 14.00%
Depreciation 3 3 2 1 1 1 1 1 1 1 1 1 1 0 0
Interest 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0

Profit and Earnings

Profit Before Tax 26 1 -3 0 3 1 2 -4 0 -3 -5 1 6 10 10
Tax 5 -1 4 0 1 0 -1 1 0 -1 -2 0 2 2 3
Net Profit 21 2 -7 0 2 1 2 -5 -1 -1 -4 1 4 8 8
EPS 3.89 0.32 -1.30 0.04 0.42 0.16 0.54 -1.09 -0.13 -0.33 -0.81 0.24 1.31 2.41 4.70

Valiant Laboratories Cash Flow Screener - Liquidity Fundamentals

Screen VALIANTLAB cash flow statements and liquidity fundamentals. Analyze operating, investing, and financing activities using our stock screener for share price strength and price trend assessment against the wider stock market and other stocks.

In 2025-March, operating activities generated ₹1, and net cash flow was an outflow of ₹7.

Over the same period, investing activities used ₹53 and financing activities provided ₹45.

Item 2025-March 2024-March 2023-March

Cash from Operations and Investing

Operating Activities 1 2 56
Investing Activities -53 -144 -55

Financing and Net Cash

Financing Activities 45 152 -1
Net Cash Flow -7 11 0

Valiant Laboratories Shareholding Pattern Screener

See Valiant Laboratories shareholding pattern with promoter, FII, and DII holdings. Check Valiant Laboratories promoter holding and ownership changes for VALIANTLAB on TickJournal, and see how institutional stock price moves affect the market.

In 2026-Mar, promoters held 74.94%, foreign institutions 0.20%, domestic institutions 0.00% and the public 18.53%, spread across 14,657 shareholders.

The shareholder count was 14,657 in 2026-Mar, compared with 14,341 in 2026-Jun.

Item 2026-Mar 2026-Jun 2025-Mar 2025-Jun 2025-Aug 2025-Sept 2025-Dec 2024-Mar

Promoter Holding

Promoter Holding 74.94% 74.94% 74.94% 74.94% 74.94% 74.94% 74.94% 74.94%

Institutional Investors

FII Holding 0.20% 0.00% 0.64% 0.63% 0.52% 0.02% 0.01% 3.48%
DII Holding 0.00% 0.00% 0.00% 0.46% 0.00% 0.00% 0.00% 0.03%

Government, Public and Others

Govt Holding 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Public Holding 18.53% 18.91% 16.28% 17.05% 17.08% 18.19% 18.51% 15.16%
Other Holding 6.33% 6.15% 8.13% 6.92% 7.46% 6.85% 6.55% 6.39%
Shareholder Count 14,657 14,341 15,036 14,432 14,948 15,075 14,910 14,914

Dividend Yield Screener - Share Price & Share Analysis

Check the dividend history with payout and yield data. View dividend details including ex-dates, the dividend rate, and amounts paid by Valiant Laboratories. Valiant Laboratories dividend yield can be compared with peers and other stocks in the market.

No dividends declared by Valiant Laboratories.

Valiant Laboratories Stock Index Membership - Nifty & Sensex

See which indices include Valiant Laboratories stock. Check VALIANTLAB index membership in NIFTY 50, SENSEX, and other indices on TickJournal, and compare the Nifty trend with the broader market trend.

Complete Index List

Valiant Laboratories is not part of any tracked indices.
Only major market indices are tracked in our system.

Valiant Laboratories Market Events Screener - Corporate Actions

Get Valiant Laboratories corporate actions including splits, bonuses, and buybacks disclosed to the exchange. Check Valiant Laboratories stock events that may affect VALIANTLAB share price, along with derivatives, futures and options activity and sector gainers.

12 corporate actions are listed, the most recent entry being Annual General Meeting dated September 28, 2026, with a record date of September 28, 2026.

It is followed by Quarterly Result Announcement dated August 10, 2026 and Quarterly Result Announcement dated May 14, 2026.

Announcement Date Record Date Event Type Information Price Impact
2026-09-28 2026-09-28 Annual General Meeting NA 24.27%
2026-08-10 2026-08-10 Quarterly Result Announcement NA 1.14%
2026-05-14 2026-05-14 Quarterly Result Announcement NA -1.81%
2026-02-11 2026-02-11 Quarterly Result Announcement NA 9.53%
2025-11-11 2025-11-11 Quarterly Result Announcement NA -1.78%
2025-09-25 2025-09-25 Annual General Meeting NA 2.09%
2025-08-08 2025-08-08 Quarterly Result Announcement NA 4.19%
2025-07-18 2025-07-19 Rights 1:4 -1.71%
2025-05-20 2025-05-20 Quarterly Result Announcement NA 3.47%
2025-02-07 2025-02-07 Quarterly Result Announcement NA 6.48%
2024-11-12 2024-11-12 Quarterly Result Announcement NA -3.96%
2024-08-08 2024-08-08 Annual General Meeting NA -13.07%

Valiant Laboratories Competitors Screener - Peer Stocks Comparison

Screen VALIANTLAB competitors and compare share prices across peer stocks. Use our screener to analyze sector peers, fundamentals, and relative performance, from valuation and price target to the future price outlook, for better stock selection in a changing stock market.

The comparison table covers 10 companies in the Healthcare sector, shown with market capitalisation, P/E ratio, revenue, growth, net profit and RSI.

Company Market Cap P/E Ratio Revenue YoY Growth Net Profit RSI
Sun Pharmaceutical 447,476 36.44 61,674 12.69% 11,565 47.42
Divis Laboratories 250,363 86.51 11,067 13.95% 2,568 58.71
Torrent Pharmaceuticals 186,152 85.91 13,886 20.34% 2,138 48.14
Zydus Life Science 120,798 26.32 27,658 17.64% 5,026 61.81
Cipla 111,426 33.44 29,045 2.24% 3,870 44.03
Laurus Labs 106,838 99.70 6,868 22.01% 890 58.00
Mankind Pharma 105,107 48.73 14,636 14.85% 1,938 64.24
Dr Reddys Laboratories 104,492 32.05 35,059 3.90% 4,158 69.59
Aurobindo Pharma 97,682 26.36 34,145 5.56% 3,503 54.69
Lupin 93,829 16.99 29,039 26.75% 5,356 34.02

Valiant Laboratories Company Announcements - News & Reports Screener

Screen VALIANTLAB latest company announcements and news updates. Filter stock news, results, and material events using our screener for share price impact analysis, and review the option chain for related stocks. Compare other stocks in the same sector.

20 recent announcements are listed, the latest dated .

The next most recent announcements are dated and .

Date Update Actions
Closure of Trading Window -
Shareholder Meeting / Postal Ballot-Scrutinizers Report -
Shareholder Meeting / Postal Ballot-Scrutinizers Report -
2026-10-05 Shareholder Meeting / Postal Ballot-Outcome of AGM -
2026-09-17 Board Meeting Outcome for Investment In AMPYR Renewable Energy Resources Twelve A Private Limited -
2026-09-17 Announcement under Regulation 30 (LODR)-Acquisition -
2026-09-04 Announcement under Regulation 30 (LODR)-Newspaper Publication -
2026-09-03 Announcement under Regulation 30 (LODR)-Credit Rating -
2026-09-03 Letter To Shareholders -
2026-09-03 Notice Of 5Th Annual General Meeting And Annual Report For FY 2025-26 -
2026-09-03 Reg. 34 (1) Annual Report. -
2026-08-31 Announcement under Regulation 30 (LODR)-Newspaper Publication -
2026-08-12 Announcement under Regulation 30 (LODR)-Newspaper Publication -
2026-08-10 Announcement under Regulation 30 (LODR)-Monitoring Agency Report -
2026-08-10 Opening Of A New Corporate Office Of The Company -
2026-08-10 Announcement under Regulation 30 (LODR)-Change in Registered Office Address -
2026-08-10 Announcement under Regulation 30 (LODR)-Acquisition -
2026-08-10 Announcement under Regulation 30 (LODR)-Change in Directorate -
2026-08-10 For Quarter Ended June 30 2026. -
2026-08-10 Board Meeting Outcome for Audited Standalone And Consolidated Financial Results For Quarter Ended June 30 2026. -

Frequently Asked Questions

How is the company valued right now?

The current quote is ₹107.87, within a 52-week range of ₹50.93 to ₹107.87. The P/E ratio is 40.56 and the P/B ratio is 2.09, with earnings per unit of ₹-0.51. Market capitalisation stands at ₹663.64 Cr. The company operates in the Healthcare sector, in the Pharmaceuticals industry, so compare these ratios with its sector peers in the table above.

About This Data

Quotes are sourced from the NSE and the BSE. Key statistics were last updated on October 6, 2026. This page covers 4 balance sheet periods, 15 income statement periods, 3 cash flow years and 8 shareholding periods. Information is provided for research and is not investment advice.